



International Journal of Pharmaceutical Research and Development (IJPRD)

Platform for Pharmaceutical Researches & Ideas

www.ijprd.com

SYNTHESIS, EVALUATION AND ANTIMICROBIAL ACTIVITY OF 5-METHYL DISUBSTITUTED BENZOXAZOLE DERIVATIVES

Deepak Shrivastava^{1*}, Atul Sethi¹

¹Indore Institute of Pharmacy (IIP) Indore Rau-Pithampur Road Indore (M.P.), India

ABSTRACT

New 5methyl substituted phenol benzoxazoles derivatives were synthesized by the reaction of 5-methyl 2- amino phenol with various aldehydes in the presence of ethyl alcohol and lead tetra acetate. All the compounds were characterized by their analytical and spectral (IR, ¹HNMR and Mass) data. Synthesized compounds have been evaluated for their antimicrobial (gram +ve and gram – ve) and antifungal activities (C. Albicans) by standard method at 50µg/ml and 100µg/ml concentration. Benzoxazole derivatives (DS-1 to DS-8) shown significant activity as compared to Griseofulvin standard drugs.

Key words: Antimicrobial activity, Antifungal activity, Benzoxazole.

Correspondence to Author



Deepak Shrivastava

Indore Institute of Pharmacy (IIP)
Indore Rau-Pithampur Road Indore
(M.P.), India

Email:

deepakshrivastav2006@yahoo.co.in

INTRODUCTION

The rising prevalence of multi drug resistant microbial strains such as methicillin-resistant staphylococcus aureus and staphylococcus epidermis and vancomycin-resistant Enterococcus is a problem of ever increasing significance [1-4]. Although antimicrobial-resistance was recognized soon after the development of sulphonamide and penicillin [5-8].

Benzoxazoles ring is one of the most common heterocyclic in medicinal chemistry .Previous reported revealed that substituted benzoxazoles possess diverse chemotherapeutic activity

including antibiotic [9], antimicrobial [10-14], and antiviral [15-17]

In previous studies some compounds which bearing hydrogen, chlorine, methyl and nitro substitution at the 5th position on the benzoxazoles ring and their antimicrobial activity in some gram positive and gram negative bacteria and Candida albicans [18-20] were carried out.

Recently reported the synthesis and antimicrobial activity of various 5 – or 6 - methyl -2 – (p-substituted benzyl), 2- (p-substituted phenoxy methyl), and 2-thio phenoxy methyl benzoxazoles and or benzimidazoles [21].

The present work aimed to synthesize a new series of 5-methyl-2 amino phenol Benzoxazoles derivatives in order to determine their antimicrobial activities and feasible structure activity relationship.

On the basis of above description we have synthesized a different series of benzoxazoles derivative substituted at 2, 3 and 4th position and evaluated for their antimicrobial activity at different gram positive, gram negative and fungus. Comparisons of these compounds have done with control and different standard drugs.

EXPERIMENTAL WORK

Chemistry


The starting materials were commercially available. The general synthetic strategy employed to prepare the benzoxazole derivatives was based on Schiff-base dehydrogenation. Melting points were measured on a veego Amp-1 melting point apparatus. Thin layer chromatography (TLC, silica gel-G) was used to monitor reactions and check

product homogeneity. IR spectra were recorded in KBr pellets using a shimadzu model 470 spectrometer. ¹H-NMR spectra were recorded on a JEOL GSX 270 MHz spectrometer (tetramethylsilane as internal standard). Splitting patterns are described as singlet (s), doublet (d) and multiplet (m). NMR values are given in δ units relative to CDCl₃. Mass spectroscopy (m/z) spectra were obtained using a Hewlett Packard HP 5971A with mass selective Detector.

General Synthesis Procedure of DS-1 to DS-8

Aldehyde substituent's (0.01 mol) was added to mixture of 5-methyl 2-amino phenol (0.01mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed acetate (0.01mol) was added to the mixture of corresponding Schiff base (0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol final compound was obtained (Figure 1).

Figure 1. General synthesis scheme of compounds DS-1 to DS-8



Synthesis of 6-methyl-2-phenyl benzoxazole (compd. DS-1)

Benzaldehyde (1.2ml, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base (1.28g,0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-1 was obtained (Figure 1). The purity of synthesized compounds determined by TLC using silica gel-G as stationary phase and chloroform as mobile phase and iodine vapour was used as determine agent. Yield 78%; m.p. 162-164°C; λ_{\max} 367.5 nm; IR (KBr): 3015 cm⁻¹ (C-H Ar), 2905 cm⁻¹ (C-H Aliphatic), 162 cm⁻¹ (C=C), 1520 cm⁻¹ (N-H), 1014 cm⁻¹ (C-N, Aliphatic); ¹H NMR (CDCl₃) δ : 8.1-8.6 (m, 2H), 7.1-7.8 (m, 3H), 6.5-6.9 (m, 3H), 2.33(s, 1H); Mass (m/z): 286.0

Synthesis of 6 methyl-2-p-tolyl-benzoxazole (compd. DS-2)

4 Methyl-benzaldehyde (1.28g, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base (1.30g, 0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-2 was obtained (Figure 1).Yield 82%; m.p. 175 -177°C; λ_{\max} 352nm; IR(KBr): 3402cm⁻¹ (O-H), 3032cm⁻¹ (C-H, Ar), 2988cm⁻¹ (C-H, Aliphatic), 1627cm⁻¹ (C=C, Ar), 1580cm⁻¹ (N-H), 1043 cm⁻¹ (C-N), 815cm⁻¹ (C-H); ¹H NMR (CDCl₃) δ : 8.1-8.6 (m, 2H), 7.1-7.8 (m, 3H), 6.6-6.8 (m, 3H), 2.2-2.5 (s, 1H); Mass (m/z): 326.

Synthesis of 4-(6-Methyl benzoxazoles-2-yl) phenol (compd. DS-3)

Available online on www.ijprd.com

4-Hydroxy-benzaldehyde(1.28g, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base (1.26g, 0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-3 was obtained(Figure 1).Yield 62%; m.p. 180-182°C; λ_{\max} 341.5nm; IR (KBr): 3290-3373cm⁻¹ (O-H), 2908cm⁻¹ (C-H), 1622cm⁻¹ (C=C, Ar), 1560cm⁻¹ (N-H) ; ¹H NMR (CDCl₃) δ : 7.3(m,1H), 6.4-6.6 (m, 6H), 5.566(C-OH, Ar); Mass (m/z): 339.0

Synthesis of 3-(6-Methyl benzoxazoles-2-yl) phenol (compd. DS-4)

3-Hydroxy-benzaldehyde (1.28g, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base (1.26g, 0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-4was obtained.(Figure 1).Yield 65%; m.p. 158-160 °C; λ_{\max} 360nm; IR (KBr): 3297-3396cm⁻¹ (O-H), 3030cm⁻¹ (C-H, Ar), 2945cm⁻¹ (C-H, Aliphatic), 1627cm⁻¹ (C=C, Ar), 1578cm⁻¹ (N-H) 1079cm⁻¹ (C-N, Aliphatic) ; ¹H NMR (CDCl₃) δ : 8.2-8.6 (m, 3H), 7.0-7.9 (m, 2H), 6.4-6.9 (m, 2H), 2.0-2.5 (s, 1H); Mass (m/z): 349.

Synthesis of 2-(4-Bromo-phenyl)-6-Methyl Benzoxazole (compd. DS-5)

4-Bromo-benzaldehyde (1.32g, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate(4.23g, 0.01mol)

was added to the mixture of corresponding Schiff base (1.31g, 0.01mol) in glacial acetic acid(12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-5 was obtained. (Figure1).Yield 60%; m.p. 148-149°C; λ_{\max} 326 nm; IR (KBr): 3508-3650cm⁻¹ (O-H), 3024cm⁻¹ (C-H, Ar), 2924cm⁻¹ (C-H, Aliphatic), 1614cm⁻¹ (C=C, Ar), 1550cm⁻¹ (N-H), 1068cm⁻¹ (C-N), 523-600cm⁻¹ (C-Br); ¹H NMR (CDCl₃) δ : 8.0-8.1(m, 3H,), 7.1-7.6 (m, 2H), 2.5 (s, 1H); Mass (m/z): 439.0

Synthesis of 2-(4-chloro-phenyl)-6-Methyl Benzoxazole (compd. DS-6)

4-Chloro-benzaldehyde (1.38g, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base(1.18g, 0.01mol) in glacial acetic acid(12 ml) and after waiting an few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-6 was obtained. (Figure 1). Yield 62%; m.p. 152-154°C; λ_{\max} 309.5 nm; IR (KBr): 3253-3650cm⁻¹ (O-H), 3030cm⁻¹ (C-H, Ar), 2881cm⁻¹ (C-H, Aliphatic), 1616cm⁻¹ (C=C), 1044cm⁻¹ (C-N, Aliphatic), 671cm⁻¹ (C-Cl); ¹H NMR (CDCl₃) δ : 8.14-8.19 (m, 3H), 7.1-7.6 (m, 4H), 2.51 (s, 1H); Mass (m/z): 439.0

Synthesis of 2-(4-fluoro-phenyl)-6-Methyl Benzoxazole (compd. DS-7)

4-Fluoro-benzaldehyde (1.25ml ,0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol) was added to the mixture of corresponding Schiff base(1.21g, 0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was isolated by filtration and recrystallized from ethanol compound DS-7 was obtained (Figure Available online on www.ijprd.com

1).Yield 55%; m.p. 169-170 °C; λ_{\max} 296 nm; IR (KBr): 3286-3374cm⁻¹ (O-H), 3029cm⁻¹ (C-H, Ar), 2992cm⁻¹ (C-H, Aliphatic), 1630cm⁻¹ (C=C), 1573cm⁻¹ (N-H), 1081cm⁻¹ (C-N, Aliphatic), 1008-1173cm⁻¹ (C-F); ¹H NMR (CDCl₃) δ : 8.14-8.19 (m, 2H) , 7.1-7.6 (m, 4H), 6.7-6.8 (s, 1H), 2.33 (s, 1H); Mass (m/z): 436.0

Synthesis of 2-(2-Methoxy phenyl)-6-Methyl-Benzoxazole (compd. DS-8)

Methoxy-benzaldehyde(1.45ml, 0.01 mol) was added to mixture of 5-methyl 2-amino phenol (1.22g, 0.01 mol) in ethanol (7.5 ml) and boiled for 5 min after the residue was removed by filtration the Schiff base was obtained from crystallization in ethanol then lead tetra acetate (4.23g, 0.01mol)was added to the mixture of corresponding Schiff base(1.32g, 0.01mol) in glacial acetic acid (12 ml) and after waiting a few minutes the crude product was Isolated by filtration and recrystallized from ethanol compound DS-8 was obtained (Figure 1).Yield 50%; m.p. 180-190; λ_{\max} 328.5 nm; IR (KBr): 3354cm⁻¹ (O-H), 3035cm⁻¹ (C-H, Ar), 2960cm⁻¹ (C-H, Aliphatic), 1621cm⁻¹ (C=C), 1574cm⁻¹ (N-H), 1028cm⁻¹ (C-N, Aliphatic); ¹H NMR (CDCl₃) δ : 8.5-9.8 (m, 2H),7.0-7.8 (m, 2H), 6.6-6.9(m, 2H), 3.6-3.8 (s, 1H),2.38 (s, 1H); Mass (m/z): 449.0

Microbiology

For the antibacterial and the antimycotic assays, the compounds were dissolved in absolute ethanol (0.8mg/ml). Further dilutions of the compounds and standard drugs in the test medium were prepared at the required quantities of 400, 200, 100, 50, 25, 6.25, 3.12, 1.56, 0.78 μ g/ml concentrations. The minimum inhibitory concentrations (MICs) were determined using the two-fold-serial dilution technique (10, 17, and 18). In order to ensure that the solvent per se had no effect no bacterial growth, a control test was also performed at the same dilutions as used in our experiments and found to be inactive in culture medium.

All the compounds were tested for their in vitro growth inhibitory activity against different bacteria

and the yeast *C. albicans* RSKK 628. THE bacterial strains used are staphylococcus aureus ATCC 6538 and Bacillus subtilis ATCC 6033 as Gram-positive and Escherichia coli ATCC 10536, and Ps. Aeruginosa RSKK 355 as Gram-negative bacteria. RSKK strains of the microorganisms used in this study were obtained from the culture collection of the dhanvantri research and analytical laboratory Kim, Surat, Gujrat.

Gentamicin, chloramphenicol and griseofulvin were used as control drugs. The observed data on the antimicrobial activity of the compounds and the control drugs are given in table 2.

Antibacterial Assay

The cultures were obtained in Mueller-Hinton broth (Difco) for all the bacteria after 24hrs of incubation at $37 \pm 10^\circ\text{C}$. The testing was carried out in Mueller-Hinton broth at pH 7.4 and the two-fold serial dilution technique was applied. A set of tubes containing only inoculated broth was kept as controls. After incubation for 24h at $37 \pm 1^\circ\text{C}$, the last tube with no growth of microorganisms was recorded to represent MIC expressed in $\mu\text{g/ml}$ (Table 2, 3, & 4).

Antimycotic Assay


The yeast *C. albicans* was maintained in Sabouraud dextrose broth (Difco) after incubation for 24h at $25 \pm 1^\circ\text{C}$. Testing was performed in Sabouraud dextrose broth at pH 7.4 and the two-fold serial dilution technique was applied. A set of tubes containing only inoculated broth was kept as controls. After incubation for 48h at 24°C at $25 \pm 1^\circ\text{C}$, the last tube with no growth of yeast was recorded to represent MIC expressed in $\mu\text{g/ml}$ (Table 2, 3, & 4).

RESULTS AND DISCUSSION

The benzoxazole derivatives were synthesized by the dehydrogenation of Schiff bases. The products were confirmed by chromatographic and spectral data. The melting point of all compounds was observed different from ingredients melting point which was conformed the synthesis of product. The purity of synthesized compounds was checked by Available online on www.ijprcd.com

observing single spot on TLC plate. All synthesized compounds gave only one signal spot. It means all synthesized compounds were obtained in pure form. The melting point and R_f value of all synthesized compounds are given in Table 1. The structure of synthesized compounds was determined by spectral analysis. The λ_{max} of synthesized compounds was observed at a range between 300-450nm. This range of λ_{max} showed the presence of α, β -unsaturated carbonyl moiety. The IR absorption band at 1600 cm^{-1} and 1400 cm^{-1} showed the presence of a conjugated carbonyl group ($>\text{C}=\text{O}$) and ($\text{C}=\text{C}$) respectively. The $^1\text{H NMR}$ spectrum of compounds explained the presence of two doublets of vinylic protons ($\text{CH}=\text{CH}$) at δ 8.1-8.6 (1H, αH) & δ 7.1-7.8 (1H, αH). Mass spectroscopy helps to find the molecular weight of the synthesized compounds. The benzoxazole derivatives showed the molecular ion peak that equivalent to the molecular weight of proposed compound. Hence m/z value confirms the molecular weight of the respective synthesized compounds.

The benzoxazole derivatives contain amide and α, β -unsaturated carbonyl moiety which is responsible for anti-microbial activity. The anti-microbial activities of all synthesized compounds (DS-1-DS-8,) (table-2,3,& 4) were studied using cup-plate method and minimum inhibitory concentration. The zone of inhibition and minimum inhibitory concentration were calculated against the control drugs (chloramphenicol and gentamicin) anti-fungal activity of synthesized compounds were also done by calculating the zone of inhibition against the control drug (girsoflouvin) all synthesized compounds showed significant anti-microbial activity. The compound DS-2, DS-5 and DS-8 showed more activity due to CH_3 , $-\text{Cl}$, CH_3OH groups and remaining compound DS-3, DS-4, showed moderate activity due to 4-OH and 3-OH groups DS-1, DS-6 and DS-7 showed lower activity due to $\text{C}_6\text{H}_5\text{CHO}$, Br and F groups. Hence the anti-microbial activity of the benzoxazole derivatives was increased when electron withdrawing groups present on the benzoxazole moiety.

Table 1. Melting point data of starting and synthesized compounds

S. No.	Compound	R ₁	R ₂	Appearance	Molecular formula	Yield (%)	Melting point (°C)
1	5-Methyl-2-amino phenol.	-	-	Yellow	C ₇ H ₉ NO	-	126-128
2	DS-1	-	-	Yellowish crystalline	C ₁₄ H ₁₁ NO	78	162-164
3	DS-2	-	CH ₃	Silver crystalline	C ₁₅ H ₁₃ NO	82	175-177
4	DS-3	-	OH	-	C ₁₄ H ₁₁ NO ₂	62	180-182
5	DS-4	OH	-	Yellow	C ₁₄ H ₁₁ NO ₂	65	158-160
6	DS-5	-	Br	Yellow	C ₁₄ H ₁₀ BrNO	60	148-149
7	DS-6	-	Cl	Yellow	C ₁₄ H ₁₀ ClNO	62	152-154
8	DS-7	-	F	White	C ₁₄ H ₁₀ FNO	55	169-170
9	DS-8	=O	-	Silver	C ₁₅ H ₁₃ NO ₂	50	189-190

Table 2. Antimicrobial activity data (By cup plate method) of synthesized compounds

S.No.	Name of compounds	Mean Zone of inhibition (in mm)							
		Staphylococcus Aureus (G+ve)		E. Coli (G-ve)		Bacillus Subtilis (G.+ve)		P. Aeruginosa (G-ve)	
		50µg	100µg	50µg	100µg	50µg	100µg	50µg	100µg
1	Gentamycin	20	22	-	-	18	21	-	-
2	Chloramphenicol	-	-	19	21	-	-	20	22
3	DS-1	14	16	16	18	12	10	12	15
4	DS-2	13	14	17	19	14	14	9	11
5	DS-3	16	18	14	16	12	12	11	12
6	DS-4	14	14	16	15	11	13	12	15
7	DS-5	9	11	14	15	10	16	9	11
8	DS-6	12	13	8	10	18	19	13	19
9	DS-7	13	15	10	12	9	12	11	12
10	DS-8	11	13	9	11	11	10	16	10

Table 3. Antimicrobial activity/Antifungal activity of synthesized compounds (by MIC method)

S. No.	Name of compounds	Staphylococcus Aureus (G+ve) (µg/ml)	Bacillus Subtilis (G.+ve) (µg/ml)	E. Coli (G-ve) (µg/ml)	P.Aeruginosa (G-ve) (µg/ml)	C. albicans (Fungus) (µg/ml)
1	Gentamicin	0.09	1.82	0.8	2.8	-
2	Chloramphenicol	0.06	0.82	0.6	1.4	-
3	Griseofulvin	-	-	-	-	59
4	DS-1	125	64.5	62	67	64.5
5	DS-2	64.5	32.5	78	82	32.7
6	DS-3	72.5	18.56	86	81	64.8
7	DS-4	145	64.5	65.2	86	32.5
8	DS-5	18.5	22.5	64.2	59	18.7
9	DS-6	32.5	32.5	79	72	39.34
10	DS-7	21.2	62.8	86.7	89	19.5
11	DS-8	148	70.5	89.5	71.5	35.5

Table 4. Antifungal activity data of synthesized compounds

S.No.	Name of Compounds	Mean zone of inhibition (in mm)	
		Candida Albicans	
		50 µg/ml	100 µg/ml
1	Griseofulvin	19	20
2	DS-1	10	12
3	DS-2	12	12
4	DS-3	15	17
5	DS-4	13	15
6	DS-5	09	10
7	DS-6	14	16
8	DS-7	15	13
9	DS-8	11	14

CONCLUSION

The antimicrobial activity of compounds (DS-1 – DS-8) was studied for their inhibitory effects and mean zone of inhibition in different nutrient broth medium with control drugs gentamicin, chloramphenicol and griseofulvin. These all synthesized compounds were shown antimicrobial and antifungal activity. Compounds DS-2, DS-4 and DS-8 showed moderate to good antimicrobial and antifungal activity.

ACKNOWLEDGMENT

Authors are grateful to the Indore Institute of Pharmacy, Indore for providing the necessary facilities for undergoing this research work.

We are heartily thankful to Dr. Yusuf Ali Jaliwala (Principal) and Prof. Umesh Parikh for their kind support and guidance.

We are also thankful to all the faculty members, B.Pharma Final year students 2008 batch and Mr. Sunil Rathod (Librarian) for their direct and indirect support.

REFERENCES

1. Prudhomme, M.; Guyot, G.; Jemint, J. *Antibiotics* 1986, 39, 934.
2. Oren, I.; Temiz, O.; Yalem, I.; Sener, E.; Alkin, A.; Ucaritirk, N. *Arzneim. Forsch./Drugs Res.* 1997, 1393, 47, 12.

3. Oren, I.; Temiz, O.; Yalem, I.; Sener, E.; Altanlar, N. *Eur. J. Pharm. Sci.* 1998, 7, 153.
4. Temiz-Arpaci, O.; Aki-Sener, E.; Yalcm, I.; Altanlar, N. *Arch. Pharm.* 2002, 6, 283.
5. Temiz-Arpaci, O.; Ozdemir, A.; Yalcm, I.; Yildiz, I.; Aki-Sener, E.; Altanlar, N. *Arch. Pharm.* 2005, 338, 105.
6. Vinsova, J.; Horak, V.; Buchta, V.; Kaustova, J. *Molecules*, 2005, 10, 783.
7. Akbay, A.; Oren, I.; Temiz-Arpaci, O.; Aki-Sener, E.; Yalcm, I. *Arzneim. Forsch.* 2003, 3, 54, 266.
8. Sener, E.; Ozden, S.; Yalcm, I.; Ozden, T.; Akin, A.; Yildiz, S. *FABAD J. Pharm. Sci.* 1986, 11, 190.
9. Yalcm, I.; Sener, E.; Ozden, S.; Ozden, T.; Akin, A.; Yildiz, S. *FABAD J. Pharm. Sci.*, 1986,11,257
10. Ozden, T.; Ozden, S.; Sener, E.; Yalcm, I.; Akin, A.; Yildiz, S. *FABAD J. Pharm. Sci.*, 1987, 12, 39.
11. Sener, E.; Yalcm, I.; Ozden, S.; Ozden, T. *Doga Bil. Der.* 1987, 3, 11, 391.
12. Yalcm, I.; Sener, E.; Ozden, T.; Ozden, S.; Akin, A. *Eur. J. Med. Chem.*, 1990, 25, 705.
13. Yalcm, I.; Oren, I.; Sener, E.; Akin, A.; Ucarturk, N. *Eur. J. Med. Chem.* 1992, 27, 568.
14. Oren, I.; Temiz, O.; Yalcm, I.; Sener, E.; Akin, A.; Ucarturk, N. *Arzneim. FORSH*, 1997, 1393-1397.

15. Shi, D.F.; Bradshaw, T.D.; Wrigley, S.; McCall C.J.; Fichtner, L.; Fichtner, M.F.G. *J. Med. Chem.* 1996, 39, 3375-3384.
16. Stephens, F.F.; Bower, J.D. *J. Chem. Soci.* 1949, 1, 2971-2972.
17. Kim, J.S.; Sun, q.; Galto, B.; Yu, C.; Liu, A.; Liu, L.F.; La, E.J. *Bioorg. Med. Chem.* 1996, 4, 621-630.
18. Graybill, J.R. *Clin. Infect. Dis.* 1996, 22, 166.
19. Yalcm, I.; Sener, E. *Int. J. Pharm* 1993, 98, 1-8.
20. Dunwell, D. W.; Evans, D. *J. Med. Chem.* 1977, 20, 797-801.
21. Vinsova, J.; Horak, V. *Chem. Listy* 2001, 97, 1157-1167.
